Larimar Therapeutics, Inc. (Nasdaq: LRMR), is a clinical-stage biotechnology company focused on developing treatments for complex rare diseases. The company’s lead compound, CTI-1601, is currently being evaluated in the Phase 1 clinical program as a potential treatment for Friedreich’s ataxia, a rare and progressive genetic disease.

Biotechnology

Larimar Therapeutics

Carole Ben-Maimon

Adrienne Clements-Egan

Gopi Shankar

Scott Straight

Michele Walsh

Matt Lynes

Kimberly Minger

Keith L.

Diana McCarson

Mohamed Hamdani

Noreen Scherer

Keith E. Lynch, Jr.

Jennifer Johansson

Michael Celano

Research and Development

Leadership Team

Finance and Administration

Clinical Operations

Regulatory and Quality Assurance

Teams at Larimar Therapeutics

Research and Development

Leadership Team

Finance and Administration

Clinical Operations

Regulatory and Quality Assurance